

The team at the ANZMTG are proud to share with you this edition of our newsletter highlighting our activities over the past year. We thank you for your ongoing help and support and wish everyone a safe and happy festive season and best wishes in 2017.

ANZMTG Chairman's Update

As Chairman it is my pleasure to provide a brief update on the activities of the group over this tumultuous last year. 2016 has been one of our most productive years to date, providing us with wonderful opportunities for growth and success.

We have been able to expand our Sydney offices with new permanent staff, a trend continuing into 2017. Not only are our offices growing but our membership has reached almost 1,100 members and we are now engaged with over 120 sites around the world. Many of our trials have reached significant milestones over the last year with multiple analyses and several new protocols planned for 2017.

ANZMTG now has more patients enrolled, in more sites across more countries than ever before. We acknowledge the patients, their families for choosing to join our studies, and sincerely thank the doctors, nursing staff and clinical trials' teams for their commitment to research.

We were pleased to welcome Associate Professor Victoria Atkinson, Senior Medical Oncologist at Princess Alexandra Hospital, Brisbane as an ANZMTG board member in 2016. We are grateful to have so many world leading clinicians join us, especially as 2017 is gearing up to be an exciting year for the group. We have further plans to extend, restructure and diversify our Board membership so as to increase the breadth of expertise our Board members provide.

I would also like to congratulate Peter MacCallum Cancer Centre's Professor Mark Shackleton, who has accepted the appointment as Chair-Elect of ANZMTG. Mark will commence his three year term as Chair effective from March 1, 2017.



Mark is currently a Medical Oncologist and Head of the Cancer Development and Treatment Laboratory at Peter MacCallum Cancer Centre. He has also been recently appointed as the Professor and Director of Oncology at The Alfred Hospital and Monash University in Melbourne, commencing August 2017. Prof Shackleton is a current Victorian Cancer Agency Clinical Research Fellow and a recipient of multiple research awards including a Victorian Premier's Award for Medical Research, an NHMRC Achievement Award and in 2012 received the Science Minister's Prize for Australian Life Scientist of the Year. Mark's appointments and accolades reflect his standing as an international leader in melanoma research and we welcome Mark to the ANZMTG Chair role in what will be an exciting period ahead for the group.

ANZMTG is focused ultimately on improving patient care and sees 2017 as an opportunity to increase on our already impressive portfolio of international and national partnerships and trials. We believe the need for investigator-driven, independently run clinical trials for melanoma remains as important as always, especially as we enter a new era of treatment and management for this disease. The executive committee and ANZMTG team remain as committed and dedicated as ever to the cause and look forward to working together with you in the year ahead. In closing my final report as Chairman of ANZMTG I would like to acknowledge the support I have had from Libby Paton our CEO and my fellow board members. I wish all ANZMTG members a happy Christmas and productive 2017.

Sincerely,



Professor Bryan Burmeister,
ANZMTG Chairman



Professor Mark Shackleton,
ANZMTG Chair-Elect

ANZMTG Staff

Recently ANZMTG has welcomed several new full time staff members.

The team is going through an unprecedented growth period and is restructuring to better resource the group to continue its important contributions to the clinical trial and research landscape in Melanoma.

(L to R: Libby Paton, Alex Economides, Katrina Diamante, Vikki Steel, Jennifer Kinsella, Narelle Williams and Serigne Lo)



ANZMTG - 2016 Trial Achievements

A selection of our studies are profiled below, for an overview of our entire portfolio including sub-studies please visit our website, www.anzmtg.org.

ANZMTG 01.07 – WBRTMel

Chief Investigator: Prof Gerald Fogarty
Current Accrual: 204 patients / 25 sites / 3 countries
Target Accrual: 220 patients - **Recruiting**

This world-first, single histology Whole Brain Radiotherapy Trial (WBRT) achieved the target accrual of 200 patients involving 25 hospitals across 3 countries. The target recruitment has increased to 220 patients explore the impact of Hippocampal Sparing WBRT technique on neurocognitive function. We hope to achieve the new target accrual by the end of 2017.

ANZMTG 01.09 – RTN2

Chief Investigator: A/Prof Matthew Foote
Current Accrual: 39 patients / 15 sites / 3 countries
Target Accrual: 100 patients - **Recruiting**

The RTN2 trial is currently recruiting from 15 sites, including two sites in the United States. We have received ethical approval in the United Kingdom and are in discussions with further international sites.

ANZMTG 02.09 – Mel-D

Chief Investigator: A/Prof Robyn Saw
Current Accrual: 75 patients
Target Accrual: 75 / single institution- **Completed**

This Vitamin D in melanoma trial has completed follow up, the final analysis and the publication of results is underway.

ANZMTG 01.10 – CARPETS

Chief Investigator: Prof Michael Brown
Current Accrual: 6 patients / single institution
Status: **Recruiting**

A Phase I open label study of the safety and immune effects of an escalating dose of Autologous GD2 Chimeric Antigen Receptor-Expressing Peripheral Blood T Cells in patients with Metastatic BRAF-Mutant and GD2-Positive Melanoma

ANZMTG 01.12 – EAGLE FM

Chief Investigator: Prof Andrew Spillane
Current Accrual: 41 patients / 14 sites / 6 countries
Target Accrual: 75 patients (pilot) - **Recruiting**

This surgical trial has become ANZMTG's most internationally engaged trial, with sites now active across 6 countries, with a further 4 countries interested in participating. This study has also achieved local funding internationally across multiple locations.

ANZMTG 02.12 - RADICAL

Chief Investigator: A/Prof Pascale Guitera
Current Accrual: 23 patients / 8 sites / 2 countries
Target Accrual: 266 patients - **Recruiting**

This trial of Radiotherapy vs Imiquimod topical cream for patients with complex Lentigo Maligna is now recruiting at 8 sites in Australia and New Zealand. 2017 will bring international involvement with sites in the UK, Spain and Brazil close to activation.

ANZMTG 03.12 - MelMarT

Chief Investigator: Dr Marc Moncrieff
Pilot accrual met: 400 patients / 20 sites / 5 countries
Target Accrual: 400 patients (pilot) – **Completed**

This wide local excision margin trial will compare margins for stage 1 melanoma. It will have significant cost implications for the treatment of melanoma patients globally. This year, the pilot study achieved the target recruitment of 400 patients involving 20 hospitals across 5 countries.

ANZMTG 01.13

Chief Investigator: A/Prof Anne Cust
Status: **Study completed and published**

A pilot randomised controlled trial examining the feasibility, acceptability and impact of giving information on personalised genomic risk of melanoma to the public, for motivating preventive behaviours.

<http://jco.ascopubs.org/cgi/content/short/JCO.2016.68.2278v1?rss=1>

ANZMTG 01.14 - ABC

Chief Investigator: Prof Georgina Long
Current Accrual: 70 patients / 4 sites in Australia
Target Accrual: 75 patients - **Recruiting**

2016 was a big year for the ABC Trial, with 24 out of the 70 patients recruited in this year. The trial was presented at various conferences, such as the ANZMTG 2016 ASM and Australasian Melanoma Conference. Excitedly, it was also one of ten accepted to be presented as a poster at ASCO 2016.

This combination immunotherapy trial is now close to completing its current accrual target, with recruitment expected to be completed by January 2017.

Thereafter, an extension to the ABC protocol with two additional cohorts will be opened, which will aim to observe the effects of stereotactic radiosurgery and whole brain radiotherapy combined with immunotherapies.

ANZMTG 02.14 - CombiRT

Chief Investigator: Dr Tim Wang
Current Accrual: 5 patients / 4 sites in Australia
Target Accrual: 30 patients - **Recruiting**

This novel Phase II Trial involving the combination of BRAF inhibitors and palliative radiotherapy has recruited five patients since June 2016. One new site is will be activated early in the New Year.

ANZMTG 03.14 – PRISM

Chief Investigator: Prof Michael Poulsen
Status: **Protocol in Development**

This prospective multisite evaluation of the roles of F-FDG PET and sentinel lymph node mapping ± biopsy in the diagnostic workup of Merkel Cell Carcinoma is planned for commencement in 2017.

ANZMTG 01.15 - CHARLI

Chief Investigator: Dr Shahneen Sandhu
Status: **To open in 2017**

This is a new trial evaluating combination immunotherapies for patients with stage III and IV melanoma. The protocol has been developed, funding secured and ethical approval pending. CHARLI is planned to open early 2017

If you would like to submit a new research proposal please go to www.anzmtg.org, or please email the team at anzmtg@melanoma.org.au or call on +61 2 9911 7352


ANZMTG Membership and Site Progress

There are currently 120 sites that have engaged with ANZMTG in over 24 countries across the world

New members are welcome to join ANZMTG for free at www.anzmtg.org

Location of Sites	No. of Sites Engaged
Australia	39
UK	28
USA	9
Brazil	6
Canada / Netherlands	5
Italy	4
Spain	3
Denmark/New Zealand/Norway/Poland/Sweden	2
Argentina/Austria/China/France/Germany/Japan Portugal/Serbia/Singapore/Slovenia/Ukraine	1

ANZMTG Membership Accrual 2008 - 2016



Country	Membership
Australia	752
New Zealand	71
International	259

Acknowledgements

ANZMTG wishes to acknowledge and thank a range of funders who make the running of our current melanoma trials and the development of new studies possible.

